Intensified First Cycle of Rituximab Plus Eight Cycles of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone with Rituximab Chemotherapy for Advanced-Stage or Bulky Diffuse Large B-Cell Lymphoma: A Multicenter Phase II Consortium for Improving Survival of Lymphoma (CISL) Study

PURPOSE: This phase II, open-label, multicenter study aimed to investigate the efficacy and safety of a rituximab intensification for the 1st cycle with every 21-day of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP-21) among patients with previously untreated advanc...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Yu Ri, Kim, Jin Seok, Kim, Won Seog, Eom, Hyeon Seok, Yang, Deok-Hwan, Bae, Sung Hwa, Kim, Hyo Jung, Lee, Jae Hoon, Oh, Suk-Joong, Yoon, Sung-Soo, Kwak, Jae-Yong, Choi, Chul Won, Kim, Min Kyoung, Oh, Sung Young, Kang, Hye Jin, Nam, Seung Hyun, Shim, Hyeok, Park, Joon Seong, Mun, Yeung-Chul, Suh, Cheolwon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582534/
https://www.ncbi.nlm.nih.gov/pubmed/36996864
http://dx.doi.org/10.4143/crt.2023.271

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582534/
https://www.ncbi.nlm.nih.gov/pubmed/36996864
http://dx.doi.org/10.4143/crt.2023.271

Ejemplares similares